Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

BACKGROUND An increasing number of health-care systems, both public and private, such as managed-care organizations, are adopting results from cost-effectiveness (CE) analysis as one of the measures to inform decisions on allocation of health-care resources. It is expected that thresholds for CE ratios may be established for the acceptance of reimbursement or formulary listing. OBJECTIVE This paper provides an overview of the development of and debate on CE thresholds, reviews threshold figures (i.e., cost per unit of health gain) currently proposed for or applied to resource-allocation decisions, and explores how thresholds may emerge. DISCUSSION At the time of this review, there is no evidence from the literature that any health-care system has yet implemented explicit CE ratio thresholds. The fact that some government agencies have utilized results from CE analysis in pricing/reimbursement decisions allows for retrospective analysis of the consistency of these decisions. As CE analysis becomes more widely utilized in assisting health-care decision-making, this may cause decision-makers to become increasingly consistent. CONCLUSIONS When CE analysis is conducted, well-established methodology should be used and transparency should be ensured. CE thresholds are expected to emerge in many countries, driven by the need for transparent and consistent decision-making. Future thresholds will likely be higher in most high-income countries than currently cited rules of thumb.

[1]  A. Anell,et al.  Health outcome measures used in cost-effectiveness studies: a review of original articles published between 1986 and 1996. , 2000, Health policy.

[2]  A Gafni,et al.  Opportunity costs and uncertainty in the economic evaluation of health care interventions. , 2002, Health economics.

[3]  A. Garber,et al.  Economic foundations of cost-effectiveness analysis. , 1997, Journal of health economics.

[4]  A. Williams,et al.  Calculating the global burden of disease: time for a strategic reappraisal? , 1999, Health economics.

[5]  L. Doyal,et al.  The rationing debate: Rationing within the NHS should be explicit: The case for , 1997 .

[6]  Andrew R Willan,et al.  Is there a kink in consumers' threshold value for cost-effectiveness in health care? , 2002, Health economics.

[7]  M. Johannesson,et al.  Cost-utility analysis from a societal perspective. , 1997, Health policy.

[8]  M Johannesson,et al.  Some reflections on cost-effectiveness analysis. , 1998, Health economics.

[9]  M Emmelin,et al.  How many lives is equity worth? A proposal for equity adjusted years of life saved. , 1998, Journal of epidemiology and community health.

[10]  R. Klein The case against , 1997, BMJ.

[11]  Tammy O. Tengs,et al.  One thousand health-related quality-of-life estimates. , 2000, Medical care.

[12]  K. Phillips Choices in Health Care , 1990 .

[13]  C. Bulpitt,et al.  Cost-effectiveness of the treatment of hypertension. , 1993, Clinical and experimental hypertension.

[14]  Peter E. Hilsenrath,et al.  The World Health Report 2000 , 2002 .

[15]  W. Brouwer,et al.  Rationalising rationing: economic and other considerations in the debate about funding of Viagra. , 2002, Health policy.

[16]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[17]  M. Essink‐bot,et al.  A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. , 2000, American journal of public health.

[18]  D. Raisch Understanding Quality-Adjusted Life Years and Their Application to Pharmacoeconomic Research , 2000, The Annals of pharmacotherapy.

[19]  M. Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[20]  A. Gafni,et al.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. , 1993, Journal of health economics.

[21]  J. Coast Who wants to know if their care is rationed? Views of citizens and service informants , 2001, Health expectations : an international journal of public participation in health care and health policy.

[22]  M. Johannesson,et al.  Outcome measurement in economic evaluation. , 1996, Health economics.

[23]  J. Coast,et al.  The rationing debate: Rationing within the NHS should be explicit: The case for , 1997 .

[24]  D. Schwappach,et al.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence , 2002, Health expectations : an international journal of public participation in health care and health policy.

[25]  Maiwenn J Al,et al.  Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. , 2003, Social science & medicine.

[26]  Tammy O. Tengs,et al.  Five-hundred life-saving interventions and their cost-effectiveness. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[27]  M. Johannesson At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? , 2001, European heart journal.

[28]  M Johannesson,et al.  On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.

[29]  Michael E. Chernew,et al.  Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  R. McDonald Street-level bureaucrats? heart disease, health economics and policy in a primary care group. , 2002, Health & social care in the community.

[31]  N. Devlin,et al.  Cost-effectiveness Thresholds: Economic and Ethical Issues , 2002 .

[32]  T. Brewin Monetary value of a human life. , 1978, British medical journal.

[33]  B. New,et al.  The Case Against , 2018, Journal of Pharmacy Practice and Research.

[34]  J. Sachs Macroeconomics and health: investing in health for economic development , 2002 .

[35]  Frank A. Sloan,et al.  Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .

[36]  Milton C. Weinstein,et al.  Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? , 1995 .

[37]  Milton C. Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996 .

[38]  A. Wagstaff QALYs and the equity-efficiency trade-off. , 1991, Journal of health economics.

[39]  A. Harris,et al.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). , 2001, PharmacoEconomics.

[40]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[41]  M. L. Gross Ethics, Policy, and Rare Genetic Disorders: The Case of Gaucher Disease in Israel , 2002, Theoretical medicine and bioethics.

[42]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[43]  L Sjöberg,et al.  The Cost‐Effectiveness of Lifesaving Interventions in Sweden , 1997, Risk analysis : an official publication of the Society for Risk Analysis.

[44]  David O. Meltzer,et al.  Editorial: Some reflections on cost‐effectiveness analysis , 1998 .

[45]  G H Mooney,et al.  What is the monetary value of a human life? , 1977, British medical journal.

[46]  Joseph E. Aldy,et al.  The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World , 2003 .

[47]  A Gafni,et al.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[48]  M. Johannesson,et al.  Incorporating Future Costs in Medical Cost-Effectiveness Analysis , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[49]  Graham Loomes,et al.  Valuing Life Years and QALYs: Transferability and Convertability of Values Across the UK Public Sector , 2002 .

[50]  Richard J. Zeckhauser,et al.  Critical ratios and efficient allocation , 1973 .

[51]  M A Hlatky,et al.  Task force 6: cost effectiveness of assessment and management of risk factors , 1996 .

[52]  Russ Kahan,et al.  Opportunity costs , 1998 .

[53]  I. Karlberg,et al.  Opinions of Swedish citizens, health‐care politicians, administrators and doctors on rationing and health‐care financing , 2002, Health expectations : an international journal of public participation in health care and health policy.

[54]  A H Briggs,et al.  Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. , 2001, Health economics.

[55]  B. Levine,et al.  Task Force 6: coronary artery disease. , 2005, Journal of the American College of Cardiology.

[56]  M. Johannesson The Concept of Cost in the Economic Evaluation of Health Care: A Theoretical Inquiry , 1994, International Journal of Technology Assessment in Health Care.

[57]  J. Richardson,et al.  Production gains from health care: what should be included in cost-effectiveness analyses? , 1999, Social science & medicine.

[58]  J. Newhouse US and UK health economics: two disciplines separated by a common language? , 1998, Health economics.

[59]  A. Lees,et al.  Deciding how NHS money is spent: a survey of general public and medical views , 2002, Health expectations : an international journal of public participation in health care and health policy.

[60]  C. Ham Retracing the Oregon trail: the experience of rationing and the Oregon health plan , 1998, BMJ.

[61]  A. Culyer Economics and ethics in health care , 2001, Journal of medical ethics.

[62]  V. Fuster,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. , 1996, Journal of the American College of Cardiology.